By William Meyers : Biogen Idec (NASDAQ: BIIB ) generates most of its revenue ..... approval for its hemophilia therapies. Biogen has a high trailing P/E ratio ..... expecting continued EPS growth. Biogen closed at $303.67 on July 22
time in. I moved shares of Biogen Idec Inc . (NASDAQ: BIIB ) from my relegation league ..... portfolio after selling Hilton. Biogen Idec Inc , is a biotechnology company ..... hemophilia. On July 23, 2014, Biogen reported second quarter earnings
By Balanced Investing : Biogen Idec Inc . (NASDAQ: BIIB ), another big name in the pharmaceutical ..... for both adults and children. Biogen also received the FDA approval ..... the probability of success for Biogen to make money out of its discovery
Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), GlaxoSmithKline ..... Horsemen": Regeneron ( REGN ), Gilead ( GILD ), Biogen Idec ( BIIB ) and Celgene ( CELG ). Sales of these four surpass
July 23 (Reuters) - Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis,...
comments sent the Biotech Index and bellwethers like Biogen (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), and Gilead (NASDAQ ..... biotech names, not the large cap names. Clearly, Biogen Idec 's "valuation" is less of a concern given the
Biogen Idec Inc . (NASDAQ: BIIB ) Q2 2014 Earnings Conference Call July 23, 2014 09:00 ET Executives ..... today. At this time, I would like to welcome everyone to the Biogen Idec Q2 2014 Earnings Conference Call. All lines have been placed
lines and pipeline of Biogen Idec (NASDAQ: BIIB ). This is a company ..... too low here and that BIIB is probably headed for ..... ground. Introduction : Biogen Idec reported blowout numbers today: Biogen Idec Inc . today reported second
The European Commission approves Biogen Idec 's ( BIIB +11.2% ) Plegridy ( peginterferon beta-1a ) as a treatment ..... subcutaneous injection using a prefilled syringe. Plegridy is Biogen 's fifth product offering for MS. Post your comment!
July 23 (Reuters) - Biogen Idec Inc : * Says in an investor conference call that company does not think tax inversions are an adequate rationale for business